Follow the Definium Therapeutics, Inc. share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Market capitalisation: €6bn. The latest transaction was filed on 12 August 2026 (Attribution). Among the most active insiders: Sullivan Mark. Every trade is accessible without an account.
34
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€686,200
8 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Definium Therapeutics, Inc. Strong Buy (bullish), based on 17 analysts. Average price target: US$67.47.
19Σ signal
Buys n/a€686,200 Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Definium Therapeutics, Inc. is a company focused on developing innovative therapies for the treatment of serious diseases. It is listed on the XNAS market.